Mon 3/18/2019 09:47 ET
DJIA25837.9610.340.04%TELCO168.190.690.41%GOLD1304.251.300.10%Shanghai3096.4276.482.47%
S&P 5002829.787.360.26%BANKS448.083.090.69%OIL58.890.070.12%BITCOIN3990.837.180.18%
NASDAQ7706.8818.500.24%PHARM576.680.060.01%US/EU1.130.000.00%Futures2833.884.250.15%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Nabriva Therapeutics AG - NBRV   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  
From: singhtelecom (Rep: 959)Date: 02/12/2018 07:43
Forum: Nabriva Therapeutics AG - Msg #26Thread #673990531 (Rec: 0)
VENBIO incresed 800% from 220k to 2 MILLION 1.announces that it has completed enrollment in its second lefamulin evaluation against pneumonia (LEAP 2) Phase 3 clinical trial. LEAP 2, which is designed to assess the efficacy and safety of oral lefamulin compared to oral moxifloxacin in adult patients with moderate community-acquired bacterial pneumonia (CABP), completed enrollment of 738 patients. The company anticipates topline clinical results from LEAP 2 to be available in the spring of 2018.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser singhtelecom: Reward | Watch | IgnoreNBRV: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.